Products Misoprostol tablets for medication abortion were approved in many countries in 2015 (MisoOne). This article refers to abortion. In addition, other drugs exist with other indications (gastric protection, induction of labor). Structure and properties Misoprostol (C22H38O5, Mr = 382.5 g/mol) is a synthetic derivative of prostaglandin E1 and exists as a mixture of two … Misoprostol
Definition Pharmaceutical agents are excreted primarily in the urine and, via the liver, in the bile in the stool. When excreted via the bile, they re-enter the small intestine, where they may be reabsorbed. They are transported back to the liver via the portal vein. This repetitive process is called the enterohepatic circulation. It prolongs … Enterohepatic Circulation
Products Aglepristone is commercially available as a solution for injection as a veterinary drug (alizine). It has been approved in many countries since 2004. Structure and properties Aglepristone (C29H37NO2, Mr = 431.6 g/mol) is a synthetic steroid. It has a similar structure to mifepristone (Mifegyne, RU 486). Effects Aglepristone (ATCvet QG03XB90) has antigestagagenic and antiglucocorticoid … Aglepristone
Products The so-called “morning-after pill” is commercially available in many countries in the form of tablets and film-coated tablets. It is also available in pharmacies under medical treatment or after a structured consultation with dispensing documentation. An alternative is the copper IUD (“morning-after coil”). The name “pill” is not correct from a pharmaceutical point of … Morning-After Pill for Contraception
Products Ulipristal acetate was approved in the EU in 2009 and in the United States in 2010 (ellaOne, film-coated tablets). In many countries, ulipristal acetate was registered in late 2012. Since February 1, 2016, the morning-after pill has been available in pharmacies without a doctor’s prescription after a consultation and dispensing documentation (see also under … Ulipristal Acetate
Definition The group of progesterone receptor ligands includes pure agonists, such as progesterone, pure antagonists, and selective progesterone receptor modulators (SPRMs) with agonistic and antagonistic potential. Effects Progesterone antagonism or progesterone agonism, depending on the substance and tissue. Mechanism of action Binding to the progesterone receptor. Indications and potential indications To date, only mifepristone has … Progesterone Receptor Ligands
Products Mifepristone is commercially available in tablet form (Mifegyne). It was first approved in 1988 and in many countries in 1999. Mifepristone was discovered in the 1980s at Roussel-Uclaf (RU) during the development of antiglucocorticoid agents and is therefore also known as RU 486. Structure and properties Mifepristone (C29H35NO2, Mr = 429.6 g/mol) is a … Mifepristone
